Multiple Myeloma and EasyM Resource Centre.
Featured
Minimal Residual Disease as a Primary Endpoint in Multiple Myeloma
Jenna Kerry2025-05-21T11:04:11-04:00May 21st, 2025|Publication|
Opportunities and Challenges for MRD Assessment in the Clinical Management of Multiple Myeloma
Jenna Kerry2025-05-12T11:32:03-04:00May 12th, 2025|Publication|
Publications, Posters & Case Studies
Discontinuation of Maintenance Therapy in Multiple Myeloma Guided by Multimodal Measurable Residual Disease Negativity (MRD2STOP)
Jenna Kerry2025-06-11T15:55:48-04:00June 11th, 2025|Publication|
Minimal Residual Disease as a Primary Endpoint in Multiple Myeloma
Jenna Kerry2025-05-21T11:04:11-04:00May 21st, 2025|Publication|
Blood-based Measurable Residual Disease Measurement by Clonotypic Mass Spectrometry is Prognostic in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant
Jenna Kerry2025-05-15T10:08:14-04:00May 14th, 2025|Publication|
Articles
Types of Multiple Myleoma
Jenna Kerry2025-06-18T11:08:52-04:00June 16th, 2025|
What is Minimal Residual Disease?
Iain Rogers2025-02-25T22:55:13-05:00February 24th, 2025|
Mass Spectrometry Testing in Multiple Myeloma
Iain Rogers2025-02-24T16:20:23-05:00February 11th, 2025|
M-spike and Multiple Myeloma
Iain Rogers2025-02-24T16:20:40-05:00February 5th, 2025|
Press & News
Monitoring Minimal Residual Disease in Blood with EasyM
Iain Rogers2025-03-14T11:42:06-04:00July 19th, 2024|News|
Rapid Novor Teams Up with PMCC to Evaluate EasyM™ for Multiple Myeloma Minimal Residual Disease Monitoring
Iain Rogers2025-02-24T16:13:03-05:00May 14th, 2024|News|
ASH 2023 | Dr. Ravi Vij – VJ HemeOnc
Iain Rogers2025-03-21T11:58:09-04:00December 14th, 2023|News|
Rapid Novor’s Blood Test for Multiple Myeloma Monitoring is CLIA Certified for Clinical Use in the US
Iain Rogers2025-02-28T09:24:46-05:00March 16th, 2023|News|
ASH 2022 | Dr. Ravi Vij – VJ HemeOnc
Iain Rogers2025-03-21T11:58:31-04:00December 15th, 2022|News|